370 related articles for article (PubMed ID: 23167560)
21. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan.
Kanda Y; Mineishi S; Saito T; Seo S; Saito A; Suenaga K; Ohnishi M; Niiya H; Nakai K; Takeuchi T; Kawahigashi N; Shoji N; Ogasawara T; Tanosaki R; Kobayashi Y; Tobinai K; Kami M; Mori S; Suzuki R; Kunitoh H; Takaue Y
Bone Marrow Transplant; 2001 Feb; 27(4):437-44. PubMed ID: 11313674
[TBL] [Abstract][Full Text] [Related]
22. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
[TBL] [Abstract][Full Text] [Related]
23. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
Hebart H; Kanz L; Jahn G; Einsele H
Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790
[TBL] [Abstract][Full Text] [Related]
24. Is combination antiviral therapy for CMV superior to monotherapy?
Drew WL
J Clin Virol; 2006 Apr; 35(4):485-8. PubMed ID: 16387546
[TBL] [Abstract][Full Text] [Related]
25. Treatment and prophylaxis of cytomegalovirus disease.
Levinson ML; Jacobson PA
Pharmacotherapy; 1992; 12(4):300-18. PubMed ID: 1325636
[TBL] [Abstract][Full Text] [Related]
26. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study.
Bregante S; Bertilson S; Tedone E; Van Lint MT; Trespi G; Mordini N; Berisso G; Gualandi F; Lamparelli T; Figari O; Benvenuto F; Raiola AM; Bacigalupo A
Bone Marrow Transplant; 2000 Jul; 26(1):23-9. PubMed ID: 10918402
[TBL] [Abstract][Full Text] [Related]
27. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Torres-Madriz G; Boucher HW
Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
[TBL] [Abstract][Full Text] [Related]
28. Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir.
Jabs DA
Infect Agents Dis; 1995 Sep; 4(3):131-42. PubMed ID: 8548191
[TBL] [Abstract][Full Text] [Related]
29. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.
Mylonakis E; Kallas WM; Fishman JA
Clin Infect Dis; 2002 May; 34(10):1337-41. PubMed ID: 11981729
[TBL] [Abstract][Full Text] [Related]
30. Management of cytomegalovirus disease.
Danner SA
AIDS; 1995 Dec; 9 Suppl 2():S3-S8. PubMed ID: 8775800
[TBL] [Abstract][Full Text] [Related]
31. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
Mattes FM; Hainsworth EG; Geretti AM; Nebbia G; Prentice G; Potter M; Burroughs AK; Sweny P; Hassan-Walker AF; Okwuadi S; Sabin C; Amooty G; Brown VS; Grace SC; Emery VC; Griffiths PD
J Infect Dis; 2004 Apr; 189(8):1355-61. PubMed ID: 15073671
[TBL] [Abstract][Full Text] [Related]
32. Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation.
Narimatsu H; Kami M; Kato D; Matsumura T; Murashige N; Kusumi E; Yuji K; Hori A; Shibata T; Masuoka K; Wake A; Miyakoshi S; Morinaga S; Taniguchi S
Transpl Infect Dis; 2007 Mar; 9(1):11-5. PubMed ID: 17313465
[TBL] [Abstract][Full Text] [Related]
33. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.
Gilbert C; LeBlanc MH; Boivin G
Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025
[TBL] [Abstract][Full Text] [Related]
34. Ganciclovir and foscarnet dual-therapy for cytomegalovirus encephalitis: A case report and review of the literature.
Baghban A; Malinis M
J Neurol Sci; 2018 May; 388():28-36. PubMed ID: 29627026
[TBL] [Abstract][Full Text] [Related]
35. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A
Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775
[TBL] [Abstract][Full Text] [Related]
36. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.
Bueno J; Ramil C; Green M
Paediatr Drugs; 2002; 4(5):279-90. PubMed ID: 11994033
[TBL] [Abstract][Full Text] [Related]
37. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
[TBL] [Abstract][Full Text] [Related]
38. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients.
Ljungman P; Oberg G; Aschan J; Ehrnst A; Lönnqvist B; Pauksen K; Sulila P
Bone Marrow Transplant; 1996 Sep; 18(3):565-8. PubMed ID: 8879618
[TBL] [Abstract][Full Text] [Related]
39. Foscarnet--an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation?
Ordemann R; Naumann R; Geissler G; Kroschinsky F; Bornhäuser M; Schwerdtfeger R; Ehninger G
Ann Hematol; 2000 Aug; 79(8):432-6. PubMed ID: 10985362
[TBL] [Abstract][Full Text] [Related]
40. Antiviral combination therapy for cytomegalovirus infection in high-risk infants.
Vora SB; Brothers AW; Waghmare A; Englund JA
Antivir Ther; 2018; 23(6):505-511. PubMed ID: 29790481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
